Italy Chronic Inflammatory Demyelinating Polyneuropathy Market

ID: MRFR/HC/51239-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026
Italy Chronic Inflammatory Demyelinating Polyneuropathy Market Research Report By Diagnosis Type (Electromyography, Nerve Conduction Studies, Lumbar Puncture), By Treatment Type (Immunosuppressive Therapy, Intravenous Immunoglobulin, Plasmapheresis, Corticosteroids), By Distribution Channel (Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics) and By End User (Hospitals, Research Institutions, Homecare Settings) - Growth & Industry Forecast 2025 To 2035
Italy Chronic Inflammatory Demyelinating Polyneuropathy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.61%
2024 Market Size$ 59.87 Million
2025 Market Size$ 63.83 Million
2035 Market Size$ 121.1 Million
Key Players
Bristol-Myers Squibb
Sanofi
Teva Pharmaceutical Industries
Novartis
Roche
Pfizer
Trends
  • Rising Awareness and Education
  • Advancements in Therapeutic Options
  • Focus on Personalized Medicine
Opportunities
  • Increasing Incidence Rates
  • Enhanced Diagnostic Techniques
  • Growing Patient Advocacy Groups
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Diagnosis Type (USD Million)
      1. 4.1.1 Electromyography
      2. 4.1.2 Nerve Conduction Studies
      3. 4.1.3 Lumbar Puncture
    2. 4.2 Industrial Automation & Equipment, BY Treatment Type (USD Million)
      1. 4.2.1 Immunosuppressive Therapy
      2. 4.2.2 Intravenous Immunoglobulin
      3. 4.2.3 Plasmapheresis
      4. 4.2.4 Corticosteroids
    3. 4.3 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Pharmacies
      3. 4.3.3 Online Pharmacies
      4. 4.3.4 Specialty Clinics
    4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Research Institutions
      3. 4.4.3 Homecare Settings
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sanofi (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Teva Pharmaceutical Industries (IL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eisai Co (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY DIAGNOSIS TYPE
    3. 6.3 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 ITALY MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS TYPE, 2024 (% SHARE)
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation

Italy Chronic Inflammatory Demyelinating Polyneuropathy Market By Diagnosis Type (USD Million, 2025-2035)

  • Electromyography
  • Nerve Conduction Studies
  • Lumbar Puncture

Italy Chronic Inflammatory Demyelinating Polyneuropathy Market By Treatment Type (USD Million, 2025-2035)

  • Immunosuppressive Therapy
  • Intravenous Immunoglobulin
  • Plasmapheresis
  • Corticosteroids

Italy Chronic Inflammatory Demyelinating Polyneuropathy Market By Distribution Channel (USD Million, 2025-2035)

  • Hospitals
  • Pharmacies
  • Online Pharmacies
  • Specialty Clinics

Italy Chronic Inflammatory Demyelinating Polyneuropathy Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Research Institutions
  • Homecare Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.